Ergomed PLC
LSE:ERGO
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
1 344
1 346
|
Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one ERGO stock under the Base Case scenario is 1 137.89 GBX. Compared to the current market price of 1 346 GBX, Ergomed PLC is Overvalued by 15%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Ergomed PLC
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for ERGO cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Ergomed PLC
Balance Sheet Decomposition
Ergomed PLC
Current Assets | 66.9m |
Cash & Short-Term Investments | 26m |
Receivables | 38.3m |
Other Current Assets | 2.6m |
Non-Current Assets | 66.5m |
PP&E | 5.2m |
Intangibles | 55.9m |
Other Non-Current Assets | 5.5m |
Current Liabilities | 37.3m |
Accounts Payable | 4.3m |
Accrued Liabilities | 9.5m |
Other Current Liabilities | 23.5m |
Non-Current Liabilities | 5.2m |
Long-Term Debt | 1.4m |
Other Non-Current Liabilities | 3.8m |
Earnings Waterfall
Ergomed PLC
Revenue
|
152.1m
GBP
|
Cost of Revenue
|
-90.2m
GBP
|
Gross Profit
|
61.9m
GBP
|
Operating Expenses
|
-41.1m
GBP
|
Operating Income
|
20.7m
GBP
|
Other Expenses
|
-5.7m
GBP
|
Net Income
|
15m
GBP
|
Free Cash Flow Analysis
Ergomed PLC
GBP | |
Free Cash Flow | GBP |
ERGO Profitability Score
Profitability Due Diligence
Ergomed PLC's profitability score is 62/100. The higher the profitability score, the more profitable the company is.
Score
Ergomed PLC's profitability score is 62/100. The higher the profitability score, the more profitable the company is.
ERGO Solvency Score
Solvency Due Diligence
Ergomed PLC's solvency score is 92/100. The higher the solvency score, the more solvent the company is.
Score
Ergomed PLC's solvency score is 92/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ERGO Price Targets Summary
Ergomed PLC
Dividends
Current shareholder yield for ERGO is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Ergomed Plc is a clinical stage development company, which provides specialist services to the pharmaceutical and biotechnology industries spanning all phases of clinical development, post-approval pharmacovigilance, and medical information. The company is headquartered in Guildford, Surrey. The company went IPO on 2014-07-15. The firm operates through two segments: Clinical Research Services (CRO) and Pharmacovigilance (PV). CRO segment is the process of developing medical therapies, drugs and knowledge for safe use in healthcare. PV segment is engaged in the activities relating to the detection, understanding and prevention of adverse effects or other drug-related problems throughout its lifecycle. The firm operates approximately 24 offices around the world, providing its services in over 100 countries globally. The company operates in North America, United Kingdom and Europe, Middle East and Africa, and Asia. The Company’s subsidiaries include Ergomed GmbH, Ergomed Sp. z o.o, Ergomed d.o.o. Beograd, Ergomed Clinical Research Inc., MS Clinical Services, LLC and MedSource UK Ltd.
Contact
IPO
Employees
Officers
The intrinsic value of one ERGO stock under the Base Case scenario is 1 137.89 GBX.
Compared to the current market price of 1 346 GBX, Ergomed PLC is Overvalued by 15%.